Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Non-contrast DWI for Supplemental Screening

NCT: NCT03607552 · ACTIVE_NOT_RECRUITING

NCT IDNCT03607552
StatusACTIVE_NOT_RECRUITING
Start Date2018-07-16
Completion2029-07

Brief Summary

Diffusion-weighted imaging (DWI) is a short (under 5 minutes) non-contrast MRI technique that has shown promise for the detection and characterization of breast cancer. Our preliminary data has shown that DWI holds potential for detecting mammographically and clinically-occult breast cancers. However, current technical limitations reduce the sensitivity of DWI for screening applications. The identification of a screening tool to complement mammography that is more accurate than ultrasound and faster, less expensive, and safer than conventional contrast-enhanced MRI would have significant clinical impact by improving the early detection of cancer in women with dense breasts. We hypothesize that an optimized DWI approach will enable detection of mammographically occult breast cancer in women with dense breasts with high sensitivity and low false positive rate.

Frequently Asked Questions

What is Non-contrast DWI for Supplemental Screening?

Non-contrast DWI for Supplemental Screening is a clinical trial registered under NCT03607552. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT03607552?

The current status of NCT03607552 (Non-contrast DWI for Supplemental Screening) is: ACTIVE_NOT_RECRUITING.

When did Non-contrast DWI for Supplemental Screening start?

Non-contrast DWI for Supplemental Screening started on 2018-07-16.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.